Lisata Therapeutics (LSTA) Common Equity (2016 - 2025)
Historic Common Equity for Lisata Therapeutics (LSTA) over the last 13 years, with Q3 2025 value amounting to $17.4 million.
- Lisata Therapeutics' Common Equity fell 4843.28% to $17.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $17.4 million, marking a year-over-year decrease of 4843.28%. This contributed to the annual value of $29.6 million for FY2024, which is 3858.31% down from last year.
- Latest data reveals that Lisata Therapeutics reported Common Equity of $17.4 million as of Q3 2025, which was down 4843.28% from $21.0 million recorded in Q2 2025.
- In the past 5 years, Lisata Therapeutics' Common Equity registered a high of $61.0 million during Q1 2023, and its lowest value of $17.4 million during Q3 2025.
- In the last 3 years, Lisata Therapeutics' Common Equity had a median value of $38.2 million in 2024 and averaged $38.9 million.
- Its Common Equity has fluctuated over the past 5 years, first plummeted by 2946.34% in 2024, then tumbled by 4843.28% in 2025.
- Over the past 3 years, Lisata Therapeutics' Common Equity (Quarter) stood at $48.1 million in 2023, then tumbled by 38.58% to $29.6 million in 2024, then tumbled by 41.25% to $17.4 million in 2025.
- Its last three reported values are $17.4 million in Q3 2025, $21.0 million for Q2 2025, and $25.4 million during Q1 2025.